Clinical trials: sponsored by Beijing Anzhen Hospital
Autologous Blood Transfusion
Autologous Platelet-rich Plasma (aPRP) for Complex Aortic Arch Surgerymacrovascular Operation
Perioperative blood loss continues to be a serious problem in complex aortic arch surgery using deep hypothermic circulatory arrest (DHCA). Major blood loss causes increased morbidity and mortality [1].
- Trial name
- NCT02572440
- Testing
- Sorin XTRA/Sorin Group,
- Where
- China
- Sponsor
- Beijing Anzhen Hospital
Drug Effect Disorder, Platelet Procoagulant Activity Deficiency
the Effect Between Platelet Reactivation and Antiplatelet Drugs
Different antiplatelet drugs played various role in coronary artery disease. The mechanisms were unclear. Platelet reactivation maybe was one of major causes.
- Trial name
- NCT02198053
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Beijing Anzhen Hospital
Obstructive Sleep Apnea, Ischaemic Heart Desease
Impact of Continuous Positive Airway Pressure (CPAP) Therapy on Outcomes in Patients Undergoing Coronary Revascularization
Investigators assume that continuous positive airway pressure (CPAP) therapy can reduce the mortality, stroke rate and secondary coronary surgery in CAD with obstructive sleep apnea (OSA) patients after percutaneous coronary…
- Trial name
- NCT02080156
- Testing
- CPAP
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Beijing Anzhen Hospital
Percutaneous Coronary Intervention
Twelve vs 24 Months of Dual Antiplatelet Therapy in Patients With Coronary Revascularization for In-stent Restenosis
Patients undergoing the percutaneous coronary intervention (PCI) for in-stent restenosis (ISR) are enrolled. All patients will be randomized to receive either 12 months or 24 months of dual antiplatelet therapy with a P2Y12…
- Trial name
- NCT02402491
- Testing
- 12 months of P2Y12 receptor antagonist, 24 months of P2Y12 receptor antagonist, Aspirin
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Beijing Anzhen Hospital
Atrial Fibrillation
Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
To evaluate the safety for the combination of Rivaroxaban and Ticagrel versus triple antithrombotic regimen (Vitamin K Antagonist (VKA), Clopigogrel and Aspirin) in patients with atrial fibrillation and coronary artery disease…
- Trial name
- NCT02334254
- Testing
- rivaroxaban and ticagrel therapy, triple antithrombotic regimen with warfarin, asipirin and clopidogrel
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Beijing Anzhen Hospital
Acute Aortic Dissection
Mechanism and Early Intervention Research on ALI During Emergence Surgery of Acute Stanford A Aortic Dissection
The morbidity rate of Stanford A type Acute Aortic Dissection（AAD） has been increasing, about 5-10/100,000* per year. Emergency surgery has been the main treatment for Acute Aortic Dissection, however perioperative mortality rate…
- Trial name
- NCT01894334
- Testing
- Ulinastatin, Tranexamic acid, Edaravone
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Beijing Anzhen Hospital
Diabetes Mellitus, Type 2, Depression
Web-Based Collaborative Care for Patients With Diabetes and Depression
The goal of this proposal is to integrate depression services and diabetes care methods into a web-based collaborative care system so that a single program can assist patients with diabetes and co-morbid depression.
- Trial name
- WBCC (NCT01985711)
- Testing
- web-based collaborative care, wait-list, usual diabetes outpatient care
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Beijing Anzhen Hospital
Acute Kidney Injury
Remote Ischemic Preconditioning and Risk of Contrast-Induced Acute Kidney Injury in Patients Undergoing Coronary Stent Implantation
This single-center, randomized controlled trial is to investigate the impact of remote ischemic preconditioning (RIPC) on the risk contrast-induced acute kidney injury and its long-term impact on renal function for patients with…
- Trial name
- REPAIR (NCT01827891)
- Testing
- remote ischemic preconditioning (RIPC)
- Where
- China
- Volunteers
- 310 people
- Sponsor
- Beijing Anzhen Hospital
Coronary Heart Disease, Atherosclerosis
Fluvastatin AmelIorates aTHerosclerosis Study
The study is designed to assess the effect of statin on atherosclesrosis progression as well as to explore its potential mechanism besides lipid modifying , such as effect on inflammation and vascular calcification.
- Trial name
- FAITH (NCT01681199)
- Testing
- Fluvastatin extended release tablet
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Beijing Anzhen Hospital
Focus of Study
Effect of Atorvastatin Versus Rosuvastatin Intensive Statin Regimens on Chinese Elderly Patients Undergoing PCI
This randomized, open label, parallel-group study is designed to investigate whether periprocedural intensive statin therapy with atorvastatin versus rosuvastatin administration before PCI and 30-day continuous intensive…
- Trial name
- ARISE (NCT01646307)
- Testing
- Atorvastatin, Rosuvastatin
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Beijing Anzhen Hospital
Acute Coronary Syndrome, Angioplasty
Acute Rosuvastatin for Preventing Myocardial Damage in Patients With ACS
Rosuvastatin reload may prevent myocardial damage in ACS patients undergoing PCI
- Trial name
- AVATAR (NCT01245803)
- Testing
- additional rosuvastatin loading
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Beijing Anzhen Hospital
Myocardial Infarction
Impacts of Superselective Infarct-related Artery (IRA) Infusion of Tirofiban on Myocardial Reperfusion and Bleeding Complications in Acute Myocardial Infarction (AMI) Patients
Superselective IRA infusion of tirofiban may improve myocardial reperfusion and reduce bleeding complications in AMI patients.
- Trial name
- SUIT-AMI (NCT01181388)
- Testing
- administration of tirofiban by thrombus aspiration catheter in infarct-related artery, administration of tirofiban by guide catheter
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Beijing Anzhen Hospital